Advertisement
Articles
Advertisement

Focus on Clinical 7/21/06

Fri, 07/21/2006 - 8:04am
Cell Genesys Launches Expanded Trial
Cell Genesys Inc., South San Francisco, opened enrollment for an expanded multi-center phase I clinical trial of CG0070, an oncolytic virus therapy, to evaluate escalating doses in patients with recurrent bladder cancer.
Full Article

Exelixis Begins Phase II Trial for Kidney Cancer Compound
Exelixis Inc., South San Francisco, has launched a multi-center, open-label, phase II study of XL880, an orally bioavailable small molecule inhibitor of the receptor tyrosine kinases, in patients with hereditary or sporadic papillary renal cell carcinoma.
Full Article

deCODE Submits IND on Heart Attack Preventative
deCODE genetics, Reykjavik, Iceland, submitted an investigational new drug (IND) application to the US Food and Drug Administration (FDA) for DG051, its investigational compound to prevent heart attack, and plans to begin phase I testing of the compound later this summer.
Full Article

Fast Track Approved for TargeGen Cardiovascular Compound
TargeGen Inc., San Diego, received notification from the FDA granting a Fast Track designation for its TG100-115, to treat acute ST-elevation myocardial infarction, which is being tested in a multi-center, double blinded, phase I/II clinical trial.
Full Article

Chimerix Initiates Phase I Clinical Trial of Treatment for Smallpox
Chimerix, Inc., Durham, N.C., received FDA clearance for its IND application for CMX001, an oral antiviral drug candidate to treat smallpox infections, and will initiate a single-site phase I clinical trial to evaluate its safety.
Full Article

Genaera Begins Patient Enrollment for Macular Degeneration Trial
Genaera Corp., Plymouth Meeting, Pa., announced that it is enrolling patients in a multi-center, open-label, pharmacodynamic phase II clinical trial of Evizon (squalamine lactate) in patients with wet age-related macular degeneration.
Full Article

CuraGen Begins Phase I Trial for Skin Cancer
CuraGen Corp., Branford, Conn., said it has begun a phase I clinical trial evaluating the safety and potential activity of CR011-vcMMAE, a fully-human monoclonal antibody-drug conjugate, to treat metastatic melanoma.
Full Article

Novocell Presents Positive Phase I/II Data
Novocell Inc., Irvine, Calif., presented positive preliminary data from its phase I/II clinical trial being conducted in San Antonio, Texas, for encapsulated primary human islet allografts into patients with type I diabetes of long-standing duration.
Full Article


Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading